Share this:

Develop a pro-active market entry strategy to grow your business in the Chinese dynamic pharma environment!

About the China Market Access Conference

These past years the global pharmaceutical industry has been experiencing a shift in its development: a geographic swing away from the major mature markets - US, Japan and top 5 European countries - to a set of new dynamics in pharmerging countries.

Annual pharmaceutical sales in emerging countries are expecting to reach $400 billion by 2020, equivalent to current sales in the US and the top 5 European markets combined.

Moreover, the China pharmaceutical market is expected to hit $200 billion by 2020, making it the 2nd largest in the world, before Japan.

Your company needs to take this country into consideration for development strategies.

Are you ready for the China Market?

Why you should attend

In Europe, regulatory agencies wanting to tighten the drug approvals threaten the pharmaceutical companies settled in only one geographic area. Therefore, pharmaceutical companies are taking into consideration the opportunities of developing their business abroad.

The emerging markets - Brazil, China, India, Mexico, Russia, South Korea and Turkey - are the largest contributors to global pharmaceutical growth today. China is today in a league of its own. Massive population, aggressive government spending on healthcare and an increasing demand for drugs to treat chronic diseases make of this country the 3rd largest pharmaceutical market.

Nevertheless the environment remains complex and challenging, due to increased local competition and uncertainty around healthcare reforms.

Be sure to be aware of these dynamics and prepare your entry into new markets !

Key Highlights

This conference is organized in 4 parts related to the China-opportunities sought by European healthcare companies: